Glenmark Generics Ltd's US subsidiary (GGI) has notified that the company has started distribution of Morphine Sulfate Oral Concentrate Solution in the U.S. market through a licensing pact with a U.S. based pharmaceutical development company.
The latest introduction will be the fifth product offered by Glenmark in the segment of pain management.
The company will market Morphine Sulfate Oral Concentrate Solution in three presentations, which is indicative for the relief of severe acute and severe chronic pain.